Asia Pacific Menopausal Disorder Treatment Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2022 –2029 |
 Tamaño del mercado (año base) |
USD 2,026.59 Million |
 Tamaño del mercado (año de pronóstico) |
USD 4,097.76 Million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Mercado de tratamiento de trastornos de la menopausia en Asia y el Pacífico, por etapas (menopausia, posmenopausia, perimenopausia), tipo (terapia hormonal y terapia no hormonal), síntomas de la menopausia (síntomas vasomotores, vaginitis atrófica, osteoporosis, dolor en las articulaciones, aumento de peso, dispareunia, depresión, otros), forma farmacéutica ( comprimidos , cremas, geles, anillos/insertos, parches/películas, inyecciones, aerosoles, otros), vía de administración (oral, vaginal, transdérmica, parenteral), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros): tendencias de la industria y pronóstico hasta 2029
Análisis y tamaño del mercado
La menopausia es uno de los períodos de mayor exigencia física en la vida de una mujer, lo que ha impulsado a las compañías farmacéuticas de todo el mundo a crear medicamentos eficaces para tratarla y los problemas relacionados. La menopausia, también conocida como el período climático, se produce cuando los períodos menstruales de una mujer dejan de producirse de forma permanente. Durante este período se producen numerosos cambios significativos en el cuerpo femenino, lo que da lugar a la aparición de varias enfermedades. Los problemas de la menopausia son cada vez más comunes en todas partes del mundo, y las organizaciones sanitarias apoyan el desarrollo y el uso de medicamentos que puedan tratarlos de forma eficaz. También ha impulsado a las empresas farmacéuticas a desarrollar y comercializar medicamentos que alivien los síntomas a largo plazo de las enfermedades de la menopausia en las mujeres y que no afecten a su salud durante o después del tratamiento.
Data Bridge Market Research analiza que el mercado de tratamiento de trastornos de la menopausia en Asia-Pacífico se valoró en USD 2.026,59 millones en 2021 y se espera que alcance los USD 4.097,76 millones para 2029, registrando una CAGR del 9,20% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.
Alcance del informe y segmentación del mercado
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2022 a 2029 |
|
Año base |
2021 |
|
Años históricos |
2020 (Personalizable para 2019 - 2014) |
|
Unidades cuantitativas |
Ingresos en millones de USD, volúmenes en unidades, precios en USD |
|
Segmentos cubiertos |
Etapas (menopausia, posmenopausia, perimenopausia), tipo (terapia hormonal y terapia no hormonal), síntomas de la menopausia (síntomas vasomotores, vaginitis atrófica, osteoporosis, dolor en las articulaciones, aumento de peso, dispareunia, depresión, otros), forma farmacéutica (comprimidos, cremas, geles, anillos/insertos, parches/películas, inyecciones, aerosoles, otros), vía de administración (oral, vaginal, transdérmica, parenteral), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros) |
|
Países cubiertos |
China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC). |
|
Actores del mercado cubiertos |
Eli Lilly and Company (EE. UU.), Novo Nordisk A/S (Dinamarca), Allergan (Irlanda), Dr. Reddy's Laboratories Ltd. (India), GlaxoSmithKline plc (Reino Unido), Mylan NV (EE. UU.), Pfizer Inc. (EE. UU.), Ipsen Pharma (Francia), Abbott (EE. UU.), Besins Healthcare (Bélgica) |
|
Oportunidades de mercado |
|
Definición de mercado
El síndrome de la menopausia se refiere a los síntomas que acompañan a los cambios fisiológicos que se producen en el cuerpo de una mujer cuando sus años reproductivos llegan a su fin. La menopausia es una deficiencia hormonal femenina natural que ocurre entre los 45 y los 55 años. Es un resultado típico del proceso de envejecimiento. Los ovarios se vuelven gradualmente menos activos y producen menos hormonas sexuales durante este tiempo (estrógeno y progesterona). Como resultado, ya no es posible la menstruación. Si una mujer no ha tenido un ciclo menstrual durante un año y no hay una causa subyacente, generalmente se considera que está en la menopausia.
Dinámica del mercado de tratamiento de trastornos de la menopausia en Asia y el Pacífico
Conductores
- Aumento de la prevalencia de trastornos de la menopausia
Se estima que la creciente prevalencia de trastornos menopáusicos impulsará el crecimiento del mercado de tratamiento de trastornos menopáusicos. Junto con esto, el aumento de casos de terapia hormonal, radioterapia e histerectomía influirá en la tasa de crecimiento del mercado.
- Aumentar la inversión en infraestructura sanitaria
Otro factor importante que influye en la tasa de crecimiento del mercado de tratamiento de los trastornos de la menopausia es el creciente gasto en atención médica, que ayuda a mejorar su infraestructura.
Además, las crecientes iniciativas de organizaciones públicas y privadas para difundir la concienciación y los avances tecnológicos ampliarán el mercado de tratamiento de los trastornos de la menopausia. Además, los altos ingresos disponibles y el estilo de vida en constante cambio ampliarán el mercado de tratamiento de los trastornos de la menopausia. Junto con esto, el aumento de la población geriátrica y los casos de trastornos relacionados con las hormonas aumentarán la tasa de crecimiento del mercado.
Oportunidades
- Aumento del número de actividades de investigación y desarrollo
Además, el crecimiento del mercado se ve impulsado por un aumento en el número de actividades de investigación y desarrollo, lo que brindará oportunidades beneficiosas para el crecimiento del mercado de tratamiento de trastornos de la menopausia. Junto con esto, el aumento de las aprobaciones de medicamentos y el lanzamiento de productos innovadores impulsarán aún más la tasa de crecimiento del mercado.
Además, la creciente inversión para el desarrollo de tecnologías avanzadas y el aumento del número de mercados emergentes brindarán oportunidades beneficiosas para el crecimiento del mercado de tratamiento de los trastornos de la menopausia durante el período de pronóstico.
Restricciones/Desafíos
Por otro lado, el alto costo asociado con la terapia hormonal obstaculizará la tasa de crecimiento del mercado. La escasez de profesionales capacitados y la falta de infraestructura de atención médica en las economías en desarrollo desafiarán el mercado de tratamiento de trastornos de la menopausia. Además, la falta de conocimiento y los efectos secundarios de la medicación actuarán como freno y obstaculizarán aún más la tasa de crecimiento del mercado durante el período de pronóstico de 2022 a 2029.
Este informe de mercado sobre el tratamiento de los trastornos de la menopausia proporciona detalles de los nuevos desarrollos recientes, regulaciones comerciales, análisis de importación y exportación, análisis de producción, optimización de la cadena de valor, participación de mercado, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, análisis estratégico del crecimiento del mercado, tamaño del mercado, crecimientos del mercado por categorías, nichos de aplicación y dominio, aprobaciones de productos, lanzamientos de productos, expansiones geográficas, innovaciones tecnológicas en el mercado. Para obtener más información sobre el mercado de tratamiento de los trastornos de la menopausia, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a tomar una decisión de mercado informada para lograr el crecimiento del mercado.
Análisis de la epidemiología de los pacientes
El mercado de tratamiento de trastornos de la menopausia también le proporciona un análisis detallado del mercado para el análisis de pacientes, el pronóstico y las curas. La prevalencia, la incidencia, la mortalidad y las tasas de adherencia son algunas de las variables de datos que están disponibles en el informe. Se analizan los análisis de impacto directo o indirecto de la epidemiología en el crecimiento del mercado para crear un modelo estadístico multivariado de cohorte más sólido para pronosticar el mercado en el período de crecimiento.
Impacto de la COVID-19 en el mercado de tratamiento de trastornos de la menopausia en Asia y el Pacífico
El mercado de tratamiento de trastornos de la menopausia se ha visto paralizado por la pandemia de COVID-19, que ha provocado el cierre temporal de las instalaciones de fabricación y una caída de la demanda. Mientras el mundo intentaba detener la propagación del SARS-CoV-2, las principales corporaciones estaban trabajando para fortalecer sus redes de suministro y acelerar sus operaciones para evitar más pérdidas. Las organizaciones de atención médica en numerosas naciones de todo el mundo estaban teniendo dificultades para continuar con sus actividades de la cadena de suministro. La lentitud de la cadena de suministro también obstaculizó el mercado de tratamiento de trastornos de la menopausia. Sin embargo, ahora que las vacunas COVID-19 están fácilmente disponibles, numerosas autoridades están tratando de asegurar que los medicamentos y vacunas que salvan vidas se suministren sin interrupción. Como resultado, se espera que el mercado de tratamiento de trastornos de la menopausia se recupere más rápidamente en los próximos años.
Alcance del mercado de tratamiento de trastornos de la menopausia en Asia y el Pacífico
El mercado de tratamiento de trastornos de la menopausia está segmentado en función de las etapas, el tipo, los síntomas de la menopausia, la forma de dosificación, la vía de administración, los usuarios finales y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los segmentos de crecimiento escaso en las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.
Etapas
- Menopausia
- Posmenopausia
- Perimenopausia
Tipo
- Terapia hormonal
- Estrógeno
- Progesterona
- Combinación
- Terapia no hormonal
- Antidepresivos
- Otros
Síntomas de la menopausia
- Síntomas vasomotores
- Vaginitis atrófica
- Osteoporosis
- Dolor en las articulaciones
- Aumento de peso
- Dispareunia
- Depresión
- Otros
Forma de dosificación
- Tableta
- Cremas
- Geles
- Anillos/Insertos
- Parche/película
- Inyección de inyección
- Pulverización
- Otros
Vía de administración
- Oral
- Vaginal
- Transdérmico
- Parenteral
Usuarios finales
- Hospitales
- Clínicas de especialidades
- Cuidado domiciliario
- Otros
Canal de distribución
- Farmacia hospitalaria
- Farmacia minorista
- Farmacia en línea
- Otros
Análisis y perspectivas regionales del mercado de tratamiento de trastornos de la menopausia en Asia y el Pacífico
Se analiza el mercado de tratamiento de los trastornos de la menopausia y se proporcionan información y tendencias del tamaño del mercado por país, etapas, tipo, síntomas de la menopausia, forma de dosificación, vía de administración, usuarios finales y canal de distribución como se mencionó anteriormente.
Los países cubiertos en el informe del mercado de tratamiento de trastornos menopáusicos de Asia-Pacífico son China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas y el resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC).
Japón domina el mercado de tratamiento de los trastornos menopáusicos en Asia y el Pacífico debido a la presencia de importantes actores clave y al creciente gasto en atención médica en esta región.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia-Pacífico y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de tratamiento de trastornos de la menopausia en Asia y el Pacífico
El panorama competitivo del mercado de tratamiento de trastornos de la menopausia proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia en Asia-Pacífico, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de trastornos de la menopausia.
Algunos de los principales actores que operan en el mercado del tratamiento de los trastornos de la menopausia son:
- Mylan NV (Estados Unidos)
- Pfizer Inc. (Estados Unidos)
- GlaxoSmithKline plc (Reino Unido)
- Eli Lilly and Company (Estados Unidos)
- Abbott (Estados Unidos)
- Novo Nordisk A/S (Dinamarca)
- Allergan (Irlanda)
- Laboratorios Dr. Reddy Ltd. (India)
- Ipsen Pharma (Francia)
- Besins Healthcare (Bélgica)
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STAGES OF MENOPAUSAL DISORDER TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: REGULATIONS
6 IMPACT OF COVID-19 ON ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
6.1 PRICE IMPACT
6.2 MPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING CASES OF CHEMOTHERAPY, RADIATION THERAPY AND HYSTERECTOMY
7.1.2 GROWING CASES OF HORMONE RELATED DISORDERS IN WOMEN
7.1.3 VULNERABLE AGING POPULATION OF MENOPAUSE WOMEN
7.1.4 INCREASING ASIA-PACIFIC HEALTHCARE EXPENDITURE
7.1.5 PRESENCE OF FAVOURABLE REIMBURSEMENT
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS OF MEDICATION
7.2.2 INADEQUATE KNOWLEDGE ABOUT MENOPAUSE IN SOME DEVELOPING COUNTRIES
7.2.3 HIGH COST OF HORMONAL THERAPY
7.3 OPPORTUNITIES
7.3.1 RISING GOVERNMENT INITIATIVES TO PROMOTE WOMEN’S HEALTH
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISING AWARENESS ABOUT THE TREATMENT
7.3.4 PRESENCE OF STRONG PRODUCT PIPELINE
7.4 CHALLENGES
7.4.1 AVAILABILITY OF ALTERNATIVES
7.4.2 PATENT EXPIRY
7.4.3 SOCIAL CONCERN REGARDING MENOPAUSAL SYMPTOMS DISCUSSION
8 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES
8.1 OVERVIEW
8.2 MENOPAUSE
8.3 POSTMENOPAUSE
8.4 PERIMENOPAUSE
9 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 HORMONAL THERAPY
9.2.1 ESTROGEN
9.2.1.1β-Estradiol
9.2.1.1.1 Minivelle
9.2.1.1.2 Others
9.2.1.2 Conjugated Estrogens
9.2.1.2.1 Premarin
9.2.1.2.2 Enjuvia
9.2.1.2.3 Others
9.2.1.3 Estradiol Hemihydrate
9.2.1.3.1 Vagifem
9.2.1.3.2 Others
9.2.1.4 Esterified Estrogens
9.2.1.5 Estradiol Acetate
9.2.1.5.1 Femring
2.2.1.5.2 Others
9.2.1.6 Estropipate
9.2.1.7 Estetrol (Donesta)
9.2.2 COMBINED ESTROGENS & PROGESTOGEN DRUGS
9.2.2.1β-Estradiol (E) + Norethindrone Acetate (P)
9.2.2.1.1 Combipatch
9.2.2.1.2 Estalis
9.2.2.1.3 Others
9.2.2.2 Ethinyl Estradiol (E) + Norethindrone Acetate (P)
9.2.2.2.1 Minastrin
9.2.2.2.2 Others
9.2.2.3 Conjugated Estrogens (E) + Medroxyprogestrone Acetate (P)
9.2.2.3.1 Premphase/Prempro
9.2.2.3.2 Others
9.2.3 PROGESTOGENS
9.2.3.1 Medroxyprogesterone Acetate
9.2.3.1.1 Provera
9.2.3.1.2 Others
9.2.3.2 Micronized Progesterone
9.2.4 OTHERS
9.3 NON HORMONAL THERAPY
9.3.1 MEDICATION
9.3.1.1 Anti-Depressants
9.3.1.1.1 Brisdelle (Paroxetine)
9.3.1.1.2 Zoloft
9.3.1.1.3 Others
9.3.1.2 Ospemifene / Osphena
9.3.1.3 Gabapentin
9.3.1.4 Clonidine
9.3.1.5 Others
9.3.2 SUPPLEMENTS
9.3.2.1 Herbal Supplements
9.3.2.1.1 Ginseng
9.3.2.1.2 Ashwagandha
9.3.2.1.3 Others
9.3.2.2 Vitamin D
9.3.2.3 Others
10 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS
10.1 OVERVIEW
10.2 VASOMOTOR SYMPTOMS
10.3 ATROPHIC VAGINITS
10.4 OSTEOPOROSIS
10.5 JOINT PAIN
10.6 WEIGHT GAIN
10.7 DYSPAREUNIA
10.8 DEPRESSION
10.9 OTHERS
11 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM
11.1 OVERVIEW
11.2 TABLETS
11.3 CREAMS
11.4 GELS
11.5 RINGS/INSERTS/INSERTS
11.6 PATCH/FILMS
11.7 INJECTION SHOT
11.8 SPRAY
11.9 OTHERS
12 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 VAGINAL
12.4 TRANSDERMAL
12.5 PARENTERAL
12.5.1 SUBCUTANEOUS
12.5.2 INTRAVENOUS
12.5.3 OTHERS
13 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
14 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY GEOGRAPHY
15.1 ASIA PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 AUSTRALIA
15.1.4 INDIA
15.1.5 SOUTH KOREA
15.1.6 SINGAPORE
15.1.7 INDONESIA
15.1.8 THAILAND
15.1.9 MALAYSIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA PACIFIC
16 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 NOVARTIS AG
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 NOVO NORDISK A/S
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 MYLAN N.V.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 DR. REDDY’S LABORATORIES LTD.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ELI LILLY AND COMPANY
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 ABBOTT
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 IPSEN PHARMA
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 GLAXOSMITHKLINE PLC
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 BESINS HEALTHCARE
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 THERAPEUTICSMD, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 DUCHESNAY USA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 FERVENT PHARMACEUTICALS INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 MITHRA PHARMACEUTICALS
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 KANDY THERAPEUTICS
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SEBELA PHARMACEUTICALS
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SOJOURNIX INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 3 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES 2019-2027 (USD MILLION)
TABLE 4 ASIA-PACIFIC MENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 5 ASIA-PACIFIC POSTMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 6 ASIA-PACIFIC PERIMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 7 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2019-2027 (USD MILLION)
TABLE 8 ASIA-PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 9 ASIA-PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 10 ASIA-PACIFIC HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 11 ASIA-PACIFIC 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 12 ASIA-PACIFIC CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 13 ASIA-PACIFIC ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 14 ASIA-PACIFIC ESTRADIOL ACETATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 15 ASIA-PACIFIC HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 16 ASIA-PACIFIC 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 17 ASIA-PACIFIC ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 18 ASIA-PACIFIC CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 19 ASIA-PACIFIC HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC NON HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 22 ASIA-PACIFIC NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 23 ASIA-PACIFIC NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 24 ASIA-PACIFIC ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 27 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS 2019-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC VASOMOTOR SYMPTOMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC ATROPHIC VAGINITIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC OSTEOPOROSIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 31 ASIA-PACIFIC JOINT PAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 32 ASIA-PACIFIC WEIGHT GAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 33 ASIA-PACIFIC DYSPAREUNIA IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 34 ASIA-PACIFIC DEPRRESSION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM 2019-2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC TABLETS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC CREAMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 39 ASIA-PACIFIC GELS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 40 ASIA-PACIFIC RINGS/INSERTS/INSERTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 41 ASIA-PACIFIC PATCH/FILMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 42 ASIA-PACIFIC INJECTION SHOT IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 43 ASIA-PACIFIC SPRAY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 44 ASIA-PACIFIC OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 45 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 46 ASIA-PACIFIC ORAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 47 ASIA-PACIFIC VAGINAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 48 ASIA-PACIFIC TRANSDERMAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 49 ASIA-PACIFIC PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 50 ASIA-PACIFIC PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 51 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER 2019-2027 (USD MILLION)
TABLE 52 ASIA-PACIFIC HOSPITAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 53 ASIA-PACIFIC CLINICS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 54 ASIA-PACIFIC HOME HEALTHCARE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 55 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBITION CHANNEL, 2019-2027 (USD MILLION)
TABLE 56 ASIA-PACIFIC HOSPITAL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 57 ASIA-PACIFIC RETAIL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 58 ASIA-PACIFIC ONLINE PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 59 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 60 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 61 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 62 ASIA- PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 ASIA- PACIFIC HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 64 ASIA- PACIFIC 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 65 ASIA- PACIFIC CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 66 ASIA- PACIFIC ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 67 ASIA- PACIFIC ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 68 ASIA- PACIFIC ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 69 ASIA- PACIFIC HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 70 ASIA- PACIFIC 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 ASIA- PACIFIC ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 72 ASIA- PACIFIC CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 73 ASIA- PACIFIC HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 74 ASIA- PACIFIC MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 75 ASIA- PACIFIC NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 76 ASIA- PACIFIC NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 77 ASIA- PACIFIC ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 78 ASIA- PACIFIC NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 79 ASIA- PACIFIC HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 81 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 82 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 83 ASIA- PACIFIC PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 84 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 85 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 86 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 87 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 88 JAPAN HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 89 JAPAN HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 90 JAPAN 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 91 JAPAN CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 92 JAPAN ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 93 JAPAN ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 94 JAPAN ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 95 JAPAN HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 96 JAPAN 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 JAPAN ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 98 JAPAN CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 99 JAPAN HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 100 JAPAN MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 101 JAPAN NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 102 JAPAN NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 103 JAPAN ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 104 JAPAN NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 105 JAPAN HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 106 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 107 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 108 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 109 JAPAN PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 110 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 111 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 112 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 113 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 114 CHINA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 115 CHINA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 116 CHINA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 117 CHINA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 118 CHINA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 119 CHINA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 120 CHINA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 121 CHINA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 122 CHINA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 123 CHINA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 124 CHINA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 125 CHINA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 126 CHINA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 127 CHINA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 128 CHINA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 129 CHINA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 130 CHINA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 131 CHINA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 132 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 133 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 134 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 135 CHINA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 136 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 137 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 138 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 139 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 140 AUSTRALIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 141 AUSTRALIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 142 AUSTRALIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 143 AUSTRALIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 144 AUSTRALIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 145 AUSTRALIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 146 AUSTRALIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 147 AUSTRALIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148 AUSTRALIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 149 AUSTRALIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 150 AUSTRALIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 151 AUSTRALIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152 AUSTRALIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 153 AUSTRALIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 154 AUSTRALIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 155 AUSTRALIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 156 AUSTRALIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 157 AUSTRALIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 158 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 159 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 160 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 162 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 163 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 164 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 165 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 166 INDIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 167 INDIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 168 INDIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 169 INDIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 170 INDIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 171 INDIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172 INDIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 173 INDIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 174 INDIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 175 INDIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 176 INDIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 177 INDIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 178 INDIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 179 INDIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 180 INDIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 181 INDIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 INDIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 183 INDIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 184 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 185 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 186 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 187 INDIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 188 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 189 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 190 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 191 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 192 SOUTH KOREA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 193 SOUTH KOREA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 194 SOUTH KOREA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 195 SOUTH KOREA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 196 SOUTH KOREA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 197 SOUTH KOREA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 198 SOUTH KOREA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 199 SOUTH KOREA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 200 SOUTH KOREA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 201 SOUTH KOREA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 202 SOUTH KOREA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 203 SOUTH KOREA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 204 SOUTH KOREA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 205 SOUTH KOREA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 206 SOUTH KOREA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 207 SOUTH KOREA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 208 SOUTH KOREA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 209 SOUTH KOREA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 210 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 211 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 212 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 213 SOUTH KOREA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 214 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 215 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 216 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 217 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 218 SINGAPORE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 219 SINGAPORE HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 220 SINGAPORE 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 221 SINGAPORE CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 222 SINGAPORE ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 SINGAPORE ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 224 SINGAPORE ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 225 SINGAPORE HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 226 SINGAPORE 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 227 SINGAPORE ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 228 SINGAPORE CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 229 SINGAPORE HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 230 SINGAPORE MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 231 SINGAPORE NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 232 SINGAPORE NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 233 SINGAPORE ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 234 SINGAPORE NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 235 SINGAPORE HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 236 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 237 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 238 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 239 SINGAPORE PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 240 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 241 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 242 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 243 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 244 INDONESIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 245 INDONESIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 246 INDONESIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 247 INDONESIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 248 INDONESIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 249 INDONESIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 250 INDONESIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 251 INDONESIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 252 INDONESIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 253 INDONESIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 254 INDONESIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 255 INDONESIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 256 INDONESIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 257 INDONESIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 258 INDONESIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 259 INDONESIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 260 INDONESIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 261 INDONESIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 262 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 263 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 264 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 265 INDONESIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 266 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 267 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 268 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 269 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 270 THAILAND HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 271 THAILAND HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 272 THAILAND 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 273 THAILAND CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 274 THAILAND ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 275 THAILAND ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 276 THAILAND ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 277 THAILAND HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 278 THAILAND 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 279 THAILAND ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 280 THAILAND CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 281 THAILAND HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 282 THAILAND MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 283 THAILAND NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 284 THAILAND NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 285 THAILAND ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 286 THAILAND NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 287 THAILAND HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 288 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 289 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 290 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 291 THAILAND PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 292 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 293 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 294 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 295 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 296 THAILAND HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 297 THAILAND HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 298 THAILAND 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 299 THAILAND CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 300 THAILAND ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 301 THAILAND ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 302 THAILAND ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 303 THAILAND HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 304 THAILAND 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 305 THAILAND ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 306 THAILAND CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 307 THAILAND HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 308 THAILAND MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 309 THAILAND NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 310 THAILAND NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 311 THAILAND ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 312 THAILAND NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 313 THAILAND HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 314 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 315 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 316 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 317 THAILAND PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 318 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 319 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 320 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 321 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 322 PHILIPPINES HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 323 PHILIPPINES HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 324 PHILIPPINES 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 325 PHILIPPINES CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 326 PHILIPPINES ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 327 PHILIPPINES ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 328 PHILIPPINES ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 329 PHILIPPINES HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 330 PHILIPPINES 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 331 PHILIPPINES ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 332 PHILIPPINES CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 333 PHILIPPINES HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 334 PHILIPPINES MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 PHILIPPINES NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 336 PHILIPPINES NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 337 PHILIPPINES ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 338 PHILIPPINES NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 339 PHILIPPINES HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 340 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 341 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 342 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 343 PHILIPPINES PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 344 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 345 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 346 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 347 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 348 VIETNAM HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 349 VIETNAM HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 350 VIETNAM 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 351 VIETNAM CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 352 VIETNAM ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 353 VIETNAM ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 354 VIETNAM ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 355 VIETNAM HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 356 VIETNAM 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 357 VIETNAM ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 358 VIETNAM CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 359 VIETNAM HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 360 VIETNAM MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 361 VIETNAM NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 362 VIETNAM NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 363 VIETNAM ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 364 VIETNAM NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 365 VIETNAM HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 366 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 367 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 368 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 369 VIETNAM PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 370 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 371 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 372 REST OF ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING CASES OF HORMONE RELATED DISORDERS AND INCREASING CASES OF CHEMOTHERAPY, RADIATION THERPAY AND HYSTERECTOMY IS DRIVING THE ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 MENOPAUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
FIGURE 14 PER CAPITA HEALTHCARE EXPENDITURE IN 2018 (USD)
FIGURE 15 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, 2019
FIGURE 16 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, 2019-2027 (USD MILLION)
FIGURE 17 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, CAGR (2020-2027)
FIGURE 18 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, 2019
FIGURE 20 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 21 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 22 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, 2019
FIGURE 24 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, 2019-2027 (USD MILLION)
FIGURE 25 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, CAGR (2020-2027)
FIGURE 26 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, 2019
FIGURE 28 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, 2019-2027 (USD MILLION)
FIGURE 29 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, CAGR (2020-2027)
FIGURE 30 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 32 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 33 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 34 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, 2019
FIGURE 36 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 37 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 38 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 40 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 41 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBITION CHANNEL, CAGR (2020-2027)
FIGURE 42 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBITION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 44 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 45 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 46 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 47 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES (2020-2027)
FIGURE 48 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: COMPANY SHARE 2019 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
